After its recent funding round, HiFiBiO pens Takeda R&D collaboration

Takeda US facility
This comes after Takeda has spent billions on biotech research pacts, mergers and collaborations over the past two years (Takeda U.S. facility, Takeda)

HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda, to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.

HiFiBiO, which works on antibodies through single-B-cell screening and analysis, will receive upfront, R&D, milestone and royalty payments based on antibodies delivered to Takeda for development and sales, but both are keeping tight-lipped on just how much that’s all worth.  

In May, the Cambridge, Massachusetts-based company got off a $37.5 million series B round, coming off a 2017 management shuffle, which saw the biotech hire a new president and CEO in Liang Schweizer, Ph.D., who previously held management roles in cancer research at Sanofi and Bristol-Myers Squibb.

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

The company’s drug discovery platform, CelliGO, looks to develop therapeutic antibodies and immune system modulators through single-B-cell screening, phenotyping and analysis.

RELATED: Takeda to cut 'moderately innovative' R&D after $62B Shire buy: Reuters

Both companies said their scientists will work together to discover antibodies against Takeda’s targets using HiFiBiO Therapeutics’ single-cell screening capabilities. Takeda will be responsible for the preclinical and clinical development of the discovered antibodies.

“Takeda is a world leader in oncology, gastroenterology and neuroscience therapeutics,” said Schweizer.

“This multi-target partnership further validates our ongoing commitment to these types of open-innovation collaborations to better address unmet medical needs around the world.”

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.